Literature DB >> 14636043

Protective immunity of pneumococcal glycoconjugates.

Chi-Jen Lee1, Lucia H Lee, Carl E Frasch.   

Abstract

Pneumococcal polysaccharides (PSs), designated as T-cell independent type 2 (TI-2) antigens, induce poor immune responses in young children. Splenic marginal zone B cells, associated with CD21, CD19 and C3d, play an important role in TI-2 antibody responses, and provide host defense against bacterial pathogens. Antibody response, avidity, and opsonophagocytic activity of antisera were examined in mice immunized with type 9V PS conjugated to inactivated pneulmolysin (Ply) or to autolysin (Aly). Compared to mice given 9V PS alone, serum IgG and IgM concentrations against the 9V PS were higher in mice immunized with conjugates. High concentrations of serum antibodies were maintained for over 12 weeks. The relative avidities of IgG and IgM antibodies and opsonophagocytic activity against 9V pneumococci were high in mice immunized with conjugates. Thus, conjugate vaccines can induce high as well as long duration of antibody response and effective functional activity. In another study, mice received intranasal immunization with type 9V conjugate or 9V PS. These animals produced 9V PS IgG and IgA antibodies in their serum, spleen, intestine, lung, Peyer's patch and fecal extract samples. Mice immunized with these glycoconjugates exhibited opsonophagocytic activity and rapid bacterial clearance from blood and provided homologous and cross-protection against challenge with virulent pneumococci. These results indicate that intranasal immunization with glycoconjugate vaccines may serve as an alternative and convenient approach for prevention of pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636043     DOI: 10.1080/713608018

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  11 in total

1.  The capsular polysaccharide biosynthesis of Streptococcus pneumoniae serotype 8: functional identification of the glycosyltransferase WciS (Cap8H).

Authors:  Nehmé Saksouk; Ludovic Pelosi; Pierre Colin-Morel; Manel Boumedienne; Patricia L Abdian; Roberto A Geremia
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

Review 2.  Advances in combating fungal diseases: vaccines on the threshold.

Authors:  Jim E Cutler; George S Deepe; Bruce S Klein
Journal:  Nat Rev Microbiol       Date:  2006-12-11       Impact factor: 60.633

Review 3.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

4.  The wciN gene encodes an α-1,3-galactosyltransferase involved in the biosynthesis of the capsule repeating unit of Streptococcus pneumoniae serotype 6B.

Authors:  Weiqing Han; Li Cai; Baolin Wu; Lei Li; Zhongying Xiao; Jiansong Cheng; Peng G Wang
Journal:  Biochemistry       Date:  2012-07-13       Impact factor: 3.162

Review 5.  Pneumococcal vaccines for children and adults with bronchiectasis.

Authors:  Christina C Chang; Rosalyn J Singleton; Peter S Morris; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

6.  A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model.

Authors:  Nelly A Kuklin; Desmond J Clark; Susan Secore; James Cook; Leslie D Cope; Tessie McNeely; Liliane Noble; Martha J Brown; Julie K Zorman; Xin Min Wang; Gregory Pancari; Hongxia Fan; Kevin Isett; Bruce Burgess; Janine Bryan; Michelle Brownlow; Hugh George; Maria Meinz; Mary E Liddell; Rosemarie Kelly; Loren Schultz; Donna Montgomery; Janet Onishi; Maria Losada; Melissa Martin; Timothy Ebert; Charles Y Tan; Timothy L Schofield; Eszter Nagy; Andreas Meineke; Joseph G Joyce; Myra B Kurtz; Michael J Caulfield; Kathrin U Jansen; William McClements; Annaliesa S Anderson
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

7.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

8.  Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Takao Sugiyama; Yojiro Kawabe; Masao Katayama; Yasuo Suenaga; Akira Okamoto; Hisaji Ohshima; Yasumasa Okada; Kenji Ichikawa; Shigeru Yoshizawa; Kenji Kawakami; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-06-03       Impact factor: 5.156

9.  Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Hideko Kozuru; Yuka Jiuchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Naoya Mori; Akinori Matsumori; Koichiro Takahi; Shigeru Yoshizawa; Yojiro Kawabe; Yasuo Suenaga; Tetsuo Ozawa; Norikazu Hamada; Yasuhiro Komiya; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-12-10       Impact factor: 5.156

10.  Sequence variability is correlated with weak immunogenicity in Streptococcus pyogenes M protein.

Authors:  Jonas Lannergård; Bodil M Kristensen; Mattias C U Gustafsson; Jenny J Persson; Anna Norrby-Teglund; Margaretha Stålhammar-Carlemalm; Gunnar Lindahl
Journal:  Microbiologyopen       Date:  2015-07-15       Impact factor: 3.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.